BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38184700)

  • 1. Plasma-derived exosomal miR-326, a prognostic biomarker and novel candidate for treatment of drug resistant pediatric acute lymphoblastic leukemia.
    Saffari N; Rahgozar S; Faraji E; Sahin F
    Sci Rep; 2024 Jan; 14(1):691. PubMed ID: 38184700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous changes in expression levels of BAALC and miR-326: a novel prognostic biomarker for childhood ALL.
    Ghodousi ES; Aberuyi N; Rahgozar S
    Jpn J Clin Oncol; 2020 Jun; 50(6):671-678. PubMed ID: 32129446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA-326 and microRNA-200c: Two novel biomarkers for diagnosis and prognosis of pediatric acute lymphoblastic leukemia.
    Ghodousi ES; Rahgozar S
    J Cell Biochem; 2018 Jul; 119(7):6024-6032. PubMed ID: 29630744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miR-324-3p and miR-508-5p expression levels could serve as potential diagnostic and multidrug-resistant biomarkers in childhood acute lymphoblastic leukemia.
    Zamani A; Fattahi Dolatabadi N; Houshmand M; Nabavizadeh N
    Leuk Res; 2021 Oct; 109():106643. PubMed ID: 34147937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Expression and Clinical Significance of Exosome Derived MiR-181b-5p in Children with Acute Lymphoblastic Leukemia].
    Hong Y; Liu KK; Wang NL; Xie ZW; Chu JH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):643-648. PubMed ID: 37356920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dysregulation of miR-335-3p, targeted by NEAT1 and MALAT1 long non-coding RNAs, is associated with poor prognosis in childhood acute lymphoblastic leukemia.
    Pouyanrad S; Rahgozar S; Ghodousi ES
    Gene; 2019 Apr; 692():35-43. PubMed ID: 30639603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA expression profiles discriminate childhood T- from B-acute lymphoblastic leukemia.
    Almeida RS; Costa E Silva M; Coutinho LL; Garcia Gomes R; Pedrosa F; Massaro JD; Donadi EA; Lucena-Silva N
    Hematol Oncol; 2019 Feb; 37(1):103-112. PubMed ID: 30393877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia.
    Schotte D; De Menezes RX; Akbari Moqadam F; Khankahdani LM; Lange-Turenhout E; Chen C; Pieters R; Den Boer ML
    Haematologica; 2011 May; 96(5):703-11. PubMed ID: 21242186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of microRNA-210 on prognosis and response to chemotherapeutic drugs in pediatric acute lymphoblastic leukemia.
    Mei Y; Gao C; Wang K; Cui L; Li W; Zhao X; Liu F; Wu M; Deng G; Ding W; Jia H; Li Z
    Cancer Sci; 2014 Apr; 105(4):463-72. PubMed ID: 24720529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exosomal microRNA-107 reverses chemotherapeutic drug resistance of gastric cancer cells through HMGA2/mTOR/P-gp pathway.
    Jiang L; Zhang Y; Guo L; Liu C; Wang P; Ren W
    BMC Cancer; 2021 Dec; 21(1):1290. PubMed ID: 34856955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression analysis of circulating miR-22, miR-122, miR-217 and miR-367 as promising biomarkers of acute lymphoblastic leukemia.
    Hosseinpour-Soleimani F; Khamisipour G; Derakhshan Z; Ahmadi B
    Mol Biol Rep; 2023 Jan; 50(1):255-265. PubMed ID: 36327023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cisplatin-resistant MDA-MB-231 Cell-derived Exosomes Increase the Resistance of Recipient Cells in an Exosomal miR-423-5p-dependent Manner.
    Wang B; Zhang Y; Ye M; Wu J; Ma L; Chen H
    Curr Drug Metab; 2019; 20(10):804-814. PubMed ID: 31424364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating miR-146a expression as a non-invasive predictive biomarker for acute lymphoblastic leukemia.
    Shahid S; Shahid W; Shaheen J; Akhtar MW; Sadaf S
    Sci Rep; 2021 Nov; 11(1):22783. PubMed ID: 34815474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating exosomal microRNAs as prognostic biomarkers for non-small-cell lung cancer.
    Liu Q; Yu Z; Yuan S; Xie W; Li C; Hu Z; Xiang Y; Wu N; Wu L; Bai L; Li Y
    Oncotarget; 2017 Feb; 8(8):13048-13058. PubMed ID: 28055956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MiR-128-3p as blood based liquid biopsy biomarker in childhood acute lymphoblastic leukemia.
    Rzepiel A; Horváth A; Kutszegi N; Gézsi A; Sági JC; Almási L; Egyed B; Lőrincz P; Visnovitz T; Kovács GT; Szalai C; Semsei ÁF; Erdélyi DJ
    Mol Cell Probes; 2023 Feb; 67():101893. PubMed ID: 36640912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of miR-652-3p and Effect on Apoptosis and Drug Sensitivity in Pediatric Acute Lymphoblastic Leukemia.
    Jiang Q; Lu X; Huang P; Gao C; Zhao X; Xing T; Li G; Bao S; Zheng H
    Biomed Res Int; 2018; 2018():5724686. PubMed ID: 29967774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased level of long non coding RNA H19 is correlated with the downregulation of miR-326 and BCL-2 genes in pediatric acute lymphoblastic leukemia, a possible hallmark for leukemogenesis.
    Mofidi M; Rahgozar S; Pouyanrad S
    Mol Biol Rep; 2021 Feb; 48(2):1531-1538. PubMed ID: 33580459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating microRNAs as minimal residual disease biomarkers in childhood acute lymphoblastic leukemia.
    Rzepiel A; Kutszegi N; Gézsi A; Sági JC; Egyed B; Péter G; Butz H; Nyírő G; Müller J; Kovács GT; Szalai C; Semsei ÁF; Erdélyi DJ
    J Transl Med; 2019 Nov; 17(1):372. PubMed ID: 31727091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exosomal MiR-744 Inhibits Proliferation and Sorafenib Chemoresistance in Hepatocellular Carcinoma by Targeting PAX2.
    Wang G; Zhao W; Wang H; Qiu G; Jiang Z; Wei G; Li X
    Med Sci Monit; 2019 Sep; 25():7209-7217. PubMed ID: 31553714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating exosomal microRNAs as diagnostic and prognostic biomarkers in patients with diffuse large B-cell lymphoma.
    Cao D; Cao X; Jiang Y; Xu J; Zheng Y; Kang D; Xu C
    Hematol Oncol; 2022 Apr; 40(2):172-180. PubMed ID: 34874565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.